Cytomegalovirus immune globulin after liver transplantation: A cost-effectiveness analysis

Clinical Transplantation

Volumn 14, Issue 1, 2000, Pages 19-27

  Arbo, Manuel D J ^a   Snydman, David R ^a,b   Wong, John B ^a   Goldberg, Howard S ^a   Schmid, Christopher H ^a   Pauker, Stephen G ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness analysis; Cytomegalovirus; Cytomegalovirus immune globulin; Decision analysis; Liver transplantation; Prophylaxis

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; REGRESSION ANALYSIS; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DECISION SUPPORT TECHNIQUES; HOSPITAL COSTS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; LENGTH OF STAY; LIFE EXPECTANCY; LIVER TRANSPLANTATION; MODELS, STATISTICAL; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS;

EID: 0033967528     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2000.140105.x     Document Type: Article

References (24)

1. HO M. Cytomegalovirus. In: Greenough WBIII, Merigan TC, eds. Biology and Infection. Current Topics in Infectious Disease. New York: Plenum, 1982.
2. STRATTA RJ, SCHAEFER MS, MARKIN RS et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989: 124: 1443-1450.
3. SNYDMAN DR, WERNER BG, DOUGHERTY NN, ET AL. AND THE BOSTON CENTER FOR LIVER TRANSPLANTATION CMVIG STUDY GROUP. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993: 119: 984-991.
4. STRATTA RJ, SHAEFER MS, CHUSHING KA et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992: 127: 55-64.
5. WINSTON DJ, WIRIN D, SHAKED A, BUSUTTIL RW. Randomized comparison of ganciclovir and high dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995: 346: 69-74.
6. BADLEY AD, SEABERG EC, PORAYKO MK et al. Prophylaxis of cytomegalovirus infection in liver transplantation. A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. Transplant 1997: 64: 66-73.
7. MARTIN FM, MARTIN M, MANEZ R et al. A randomized controlled trial comparing high dose oral acyclovir to ganciclovir for the prevention of cytomegalovirus infection in adult liver transplant recipients. Transplant 1994: 58: 779-785.
8. GANE E, SALIBA F, VALDECASAS GJC, O'GRADY J, PESCOVITZ MD, LYMAN S, ROBINSON CA. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Lancet 1997: 350: 1729-1733.
9. BECK JR, PAUKER SG. The Markov process in medical prognosis. Med Decis Mak 1983: 3: 419-458.
10. SONNENBERG FA, BECK JR. Markov models in medical decision making: a practical guide. Med Decis Mak 1993: 13 (4): 322-338.
11. SONNENBERG FA, PAUKER SG. In: Salamon R, Blum B, Jorgensen M, eds. Decision Maker 6.0. Proceedings of Medinfo 86. Amsterdam: North-Holland. 1986: 1152.
12. Http://stats.bls.gov/cpihome.htm
13. Red Book, Montvale, New Jersey: Medical Economic Data, 1998.
14. GOLD MR, SIEGEL JE, RUSSELL LB, WEINSTEIN MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
15. SPSS/PC+ , V.3.1, Microsoft Corporation, 1989.
16. JAMIESON NV, FRIEND PJ, JOHNSTON PS, ALEXANDER G, BARNES ND, CALNE RY. Twenty-four years of orthotopic liver transplantation at Addenbrooke's Hospital, Cambridge. Transplant Proc 1993: 5 (1): 1102-1104.
17. BONSEL GJ, KLOMPMAKER IJ, ESSINK-BOT ML, HABBEMA JDF, SLOOFF MJH. Cost-effectiveness analysis of the Dutch liver transplantation programme. Transplant Proc 1990: 22: 1481-1484.
18. St. Anthony's DRG Guidebook 1998. Alexandria, VA: St. Anthony Publishing, 1997.
19. WEINSTEIN MC, STASON WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Ann Rev Public Health 1985: 6: 41-63.
20. KRUMHOLZ HM, PASTERNAK RC, WEINSTEIN MC et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992: 327 (1): 7-13.
21. CHURCHILL DN, LEMON BC, TORRANCE GW. A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis. Med Decis Mak 1984: 4 (4): 489-500.
22. SIMON DG. A cost-effectiveness analysis of cyclosporine in cadaveric kidney transplantation. Med Decis Mak 1986: 6: 199-207.
23. TSEVAT J, SNYDMAN DR, PAUKER SG, DURAND-ZALESKI I, WERNER BG, LEVEY AS. Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis. Transplantation 1991: 52 (2): 259-265.
24. KANKAANPÄÄ J. Cost-effectiveness of liver transplantations - how to apply the results in resource allocation. Prev Med 1990: 19: 700-704.